Omicron variant more harmless than Delta
The new year begins with good news.
Season Greetings
Merry Christmas and a Happy New Year!
Novo Holdings invests 86m in 21st.BIO
Novo Holdings is set to invest 86m in 21st.BIO A/S a new Danish bioindustrial scale-up company to boost the production of proteins.
Novartis AG snags Gyroscope for US$1.5bn
Ocular gene therapy specialist Gyroscope Therapeutics Holdings plc is to be acquired by Novartis AG for up to $1.5bn.
NorthSea Therapeutics completes US$80m Series C financing
Dutch metabolic disease specialist NorthSea Therapeutics NV has baged US$80m in a Series C fundraising co-led by Ysios Capital and Forbion Growth.
Depixus raises 30.6m in Series A financing
French-British magnetic trap specialist Depixus has raised 30,6m to develop a commercial instrument based on the companys MAGNA technology.
Ichnos Sciences in licence deal with Almirall
Ichnos Sciences Inc. has licenced the gobal rights on its IL-1RAP antagonistic antibody ISB 880 to Almirall SA for the treatment of autoimmune disorders.
Vifor Pharma Ltd to be acquired for CHF10.9bn
Biologicals and vaccine specialist CSL Ltd is set to acquire Swiss Vifor Pharma Ltd for CHF10.9bn.
Apogenix gets 25.8m cash injection for asunercept
German Apogenix AG has received a 26m in funding for a pivotal Phase III study of its CD95 ligand blocker asunercept for the treatment of COVID-19 patients.
British Adendra Therapeutics closes $53m financing
The 2021 spin out of London-based Francis Crick Institute is the very first UK company formation deal of life sciences investor ATP (Apple Tree Partners).